<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85705">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01950650</url>
  </required_header>
  <id_info>
    <org_study_id>GAPP1</org_study_id>
    <secondary_id>U1111-1136-2507</secondary_id>
    <nct_id>NCT01950650</nct_id>
  </id_info>
  <brief_title>GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus</brief_title>
  <official_title>GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <authority>France: Ministry of Health</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>India: Ministry of Health</authority>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Spain: Ministry of Health</authority>
    <authority>Turkey: Ministry of Health</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted in Asia, Europe and in the United States of America. The aim of this
      study is to examine patient and physician beliefs regarding insulin therapy and the degree
      to which patients adhere to their insulin regimens.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>Frequency of insulin omission/non-adherence</measure>
    <time_frame>In the past 30 days prior to the day when responding to the survey (patient survey)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Reasons for insulin omission/non-adherence reported by patient and physician</measure>
    <time_frame>Day 1 (when responding to the survey)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of insulin treatment on life domains (patient survey)</measure>
    <time_frame>Day 1 (when responding to the online questionnaire)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">1800</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Patients with diabetes</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Physicians</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>No treatment given</intervention_name>
    <description>Survey conducted through computer-assisted telephone interviewing.</description>
    <arm_group_label>Patients with diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>survey</intervention_name>
    <description>Survey conducted via the Internet.</description>
    <arm_group_label>Physicians</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Insulin treated patients with diabetes (type 1 or 2), and physicians involved in the
        treatment, management of diabetes and care of patients with diabetes.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PATIENTS WITH DIABETES:

          -  Age 18 years or older

          -  Treated with insulin

          -  Type 1 or Type 2 diabetes

          -  PHYSICIANS:

          -  In practice for more than 1 year since completing residency

          -  See a minimum number of patients with diabetes per week (primary care physicians 5,
             specialists 10)

          -  Initiate insulin treatment for patients with diabetes
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Clinical Trial Call Center</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris La d√©fense cedex</city>
        <zip>92932</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <zip>55127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <zip>560001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <zip>1000005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <zip>119330</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <zip>34335</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Crawley</city>
        <zip>RH11 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Japan</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 15, 2014</lastchanged_date>
  <firstreceived_date>September 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
